Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2011

01-04-2011 | Research Paper

Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression

Authors: Wei Bin Fang, Iman Jokar, Anna Chytil, Harold L. Moses, Ty Abel, Nikki Cheng

Published in: Clinical & Experimental Metastasis | Issue 4/2011

Login to get access

Abstract

Accumulation of fibroblasts is a phenomenon that significantly correlates with formation of aggressive cancers. While studies have shown that the TGF-β signaling pathway is an important regulator of fibroblast activation, the functional contribution of TGF-β signaling in fibroblasts during multi-step tumor progression remains largely unclear. In previous studies, we used a sub-renal capsule transplantation model to demonstrate that homozygous knockout of the Tgfbr2 gene (Tgbr2FspKO) enhanced mammary tumor growth and metastasis. Here, we show for the first time a significant role for loss of one Tgfbr2 allele during multi-step mammary tumor progression. Heterozygous deletion of Tgfbr2 in stromal cells in MMTV–PyVmT transgenic mice (PyVmT/Tgfbr2hetFspKO mice) resulted in earlier tumor formation and increased stromal cell accumulation. In contrast to previous studies of Tgbr2FspKO fibroblasts, Tgfbr2hetFspKO fibroblasts did not significantly increase tumor growth, but enhanced lung metastasis in PyVmT transgenic mice and in co-transplantation studies with PyVmT mammary carcinoma cells. Furthermore, Tgfbr2hetFspKO fibroblasts enhanced mammary carcinoma cell invasiveness associated with expression of inflammatory cytokines including CXCL12 and CCL2. Analyses of Tgbr2FspKO and Tgfbr2hetFspKO fibroblasts revealed differences in the expression of factors associated with metastatic spread, indicating potential differences in the mechanism of action between homozygous and heterozygous deletion of Tgfbr2 in stromal cells. In summary, these studies demonstrate for the first time that loss of one Tgfbr2 allele in fibroblasts enhances mammary metastases in a multi-step model of tumor progression, and demonstrate the importance of clarifying the functional contribution of genetic alterations in stromal cells in breast cancer progression.
Appendix
Available only for authorised users
Literature
1.
Barrett-Lee P, Travers M, Luqmani Y et al (1990) Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer 61(4):612–617PubMedCrossRef
2.
Desmouliere A, Guyot C, Gabbiani G (2004) The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48(5–6):509–517PubMedCrossRef
3.
4.
Camps J, Chang S, Hsu T et al (1990) Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 87:75–79PubMedCrossRef
5.
Sakakura T, Sakagami Y, Nishizuka Y (1981) Accelerated mammary cancer development by fetal salivary mesenchyma isografted to adult mouse mammary epithelium. J Natl Cancer Inst 66(5):953–959PubMed
6.
Shekhar MP, Werdell J, Santner SJ et al (2001) Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 61:1320–1326PubMed
7.
Kurose K, Gilley K, Matsumoto S et al (2002) Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32(3):355–357PubMedCrossRef
8.
Hagedorn H, Bachmeir B, Nerlich A (2001) Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (review). Int J Oncol 18(4):669–681PubMed
9.
Lei X, Bandyopadhyay A, Le T, Sun L (2002) Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 21:7514–7523PubMedCrossRef
10.
Tuxhorn J, McAlhany S, Yang F et al (2002) Inhibition of transforming growth factor B activity decreases angiogenesis in human prostate cancer-reactive stroma-xenograft model. Cancer Res 62:6021–6025PubMed
11.
Joseph H, Gorska AE, Sohn P et al (1999) Overexpression of a kinase-deficient transforming growth factor-B type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell 10:1221–1234PubMed
12.
Paoloni-Giacobino A, Rossier C, Papasavvas MP et al (2001) Frequency of replication/transcription errors in (A)/(T) runs of human genes. Hum Genet 109(1):40–47PubMedCrossRef
13.
Krtolica A, Parrinello S, Lockett S et al (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 98(21):12072–12077PubMedCrossRef
14.
Lawrenson K, Grun B, Benjamin E et al (2010) Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. Neoplasia 12(4):317–325PubMed
15.
Bian Y, Knobloch TJ, Sadim M et al (2007) Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development. Hum Mol Genet 16(24):3128–3135PubMedCrossRef
16.
ten Dijke P, Hill CS (2004) New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29(5):265–273PubMedCrossRef
17.
McCaffrey TA, Falcone DJ (1993) Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-beta in vascular smooth muscle cells. Mol Biol Cell 4(3):315–322PubMed
18.
Angeli F, Koumakis G, Chen MC et al (2009) Role of stromal fibroblasts in cancer: promoting or impeding? Tumour Biol 30(3):109–120PubMedCrossRef
19.
Bhowmick N, Chytiil A, Plieth D et al (2004) TGF-ß signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:847–851CrossRef
20.
Cheng N, Bhowmick NA, Chytil A et al (2005) Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24(32):5053–5068PubMedCrossRef
21.
Guy C, Cardiff R, Muller W (1992) Induction of mammary tumors by expression a polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961PubMed
22.
Lin E, Jones J, Zhu L et al (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Path 163(5):2113–2126PubMedCrossRef
23.
Sugimoto H, Mundel TM, Kieran MW et al (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5(12):1640–1646PubMedCrossRef
24.
Hayward S, Haughney PC, Rosen MA, Greulich KM, Weier HU, Dahiya R, Cunha GR (1998) Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 63(3):131–140PubMedCrossRef
25.
Tang Z, Yu M, Miller F et al (2008) Increased invasion through basement membrane by CXCL7-transfected breast cells. Am J Surg 196(5):690–696PubMedCrossRef
26.
Allinen M, Beroukhim R, Cai L et al (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6(1):17–32PubMedCrossRef
27.
Orimo A, Gupta PB, Sgroi DC et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3):335–348PubMedCrossRef
28.
Yamashiro S, Takeya M, Nishi T et al (1994) Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am J Pathol 145(4):856–867PubMed
29.
Jia GQ, Gonzalo JA, Lloyd C et al (1996) Distinct expression and function of the novel mouse chemokine monocyte chemotactic protein-5 in lung allergic inflammation. J Exp Med 184(5):1939–1951PubMedCrossRef
30.
Abramson N, Castro S, Goldstein JD (1997) Lipid-laden macrophage infiltration of human adenocarcinoma in vivo associated with taxol and GCSF treatment. Cancer Invest 15(1):18–22PubMedCrossRef
31.
Xu BJ, Yan W, Jovanovic B et al (2010) Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts. Proteomics 10:2458PubMedCrossRef
32.
Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56PubMedCrossRef
33.
Kim SY, Lee CH, Midura BV et al (2008) Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 25(3):201–211PubMedCrossRef
34.
Cheng N, Chytil A, Shyr Y et al (2007) Enhanced hepatocyte growth factor signaling by type II transforming growth factor-{beta} receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res 67(10):4869–4877PubMedCrossRef
35.
Hembruff SL, Jokar I, Yang L et al (2010) Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia 12(5):425–433PubMed
36.
Robinson S, Silberstein G, Roberts A et al (1991) Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. Development 113:867–878PubMed
37.
Cunha G, Hom Y (1996) Role of mesenchymal-epithelial interactions in mammary gland development. J Mamm Gland Biol 1(1):21–34CrossRef
38.
Gal A, Sjoblom T, Fedorova L et al (2008) Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 27(9):1218–1230PubMedCrossRef
39.
Webster M, Hutchinson JN, Rauh MJ, Muthuswamy SK, Anton A, Tortorice CG, Cardiff RD, Graham FL, Hassell JA, Muller WJ (1998) Requirement of both Shc and Phosphatidyl 3′ kinase signaling pathways in polyomavirus middle T-mediated mammar tumorigenesis. Mol Cell Biol 18(4):2344–2359PubMed
40.
Foulkes WD, Reis-Filho JS, Narod SA (2010) Tumor size and survival in breast cancer—a reappraisal. Nat Rev Clin Oncol 7(6):348–353PubMedCrossRef
41.
Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518–524PubMedCrossRef
42.
DeNardo DG, Johansson M, Coussens LM (2008) Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27(1):11–18PubMedCrossRef
43.
Allavena P, Sica A, Solinas G et al (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66(1):1–9PubMedCrossRef
44.
45.
Anders CK, Carey LA (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9(Suppl 2):S73–S81PubMedCrossRef
46.
Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG (1995) Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130(2):393–405PubMedCrossRef
47.
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239–252PubMedCrossRef
48.
Bierie B, Moses HL (2005) Under pressure: stromal fibroblasts change their ways. Cell 123(6):985–987PubMedCrossRef
49.
Fujimoto H, Sangai T, Ishii G et al (2009) Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125(6):1276–1284PubMedCrossRef
50.
Lu X, Kang Y (2009) Chemokine (C–C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284(42):29087–29096PubMedCrossRef
51.
Anastassiades OT, Pryce DM (1974) Fibrosis as in indication of time in infiltrating breast cancer and its importance in prognosis. Br J Cancer 29(3):232–239PubMedCrossRef
52.
Hasebe T, Tsuda H, Tsubono Y et al (1997) Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn J Cancer Res 88(6):590–599PubMed
53.
Tamiolakis D, Papadopoulos N, Cheva A et al (2002) Immunohistochemical expression of alpha-smooth muscle actin in infiltrating ductal carcinoma of the breast with productive fibrosis. Eur J Gynaecol Oncol 23(5):469–471PubMed
54.
Karas M, Amir H, Fishman D et al (2000) Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 36(1):101–111PubMedCrossRef
55.
Sciacca L, Costantino A, Pandini G et al (1999) Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18(15):2471–2479PubMedCrossRef
56.
Rahimi N, Saulnier R, Nakamura T et al (1994) Role of hepatocyte growth factor in breast cancer: a novel mitogenic factor secreted by adipocytes. DNA Cell Biol 13(12):1189–1197PubMedCrossRef
57.
Ma X, Norsworthy K, Kundu N et al (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8(3):490–498PubMedCrossRef
58.
Dunn SE, Ehrlich M, Sharp NJ et al (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58(15):3353–3361PubMed
59.
Sachdev D, Li SL, Hartell JS et al (2003) A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63(3):627–635PubMed
60.
Zhang X, Yang J, Li Y et al (2005) Both Sp1 and Smad participate in mediating TGF-beta1-induced HGF receptor expression in renal epithelial cells. Am J Physiol Renal Physiol 288(1):F16–F26PubMedCrossRef
61.
Chia DJ, Ono M, Woelfle J et al (2006) Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription. J Biol Chem 281(6):3190–3197PubMedCrossRef
62.
Cocolakis E, Dai M, Drevet L et al (2008) Smad signaling antagonizes STAT5-mediated gene transcription and mammary epithelial cell differentiation. J Biol Chem 283(3):1293–1307PubMedCrossRef
63.
Muraoka RS, Koh Y, Roebuck LR et al (2003) Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 23(23):8691–8703PubMedCrossRef
64.
Schade B, Lam SH, Cernea D et al (2007) Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. Cancer Res 67(16):7579–7588PubMedCrossRef
65.
Wendt MK, Johanesen PA, Kang-Decker N et al (2006) Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 25(36):4986–4997PubMedCrossRef
66.
(2007) Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791. Drugs R D 8(2):113–119
67.
De Paepe B, Creus KK, De Bleecker JL (2008) Chemokines in idiopathic inflammatory myopathies. Front Biosci 13:2548–2577PubMedCrossRef
68.
Bieche I, Chavey C, Andrieu C et al (2007) CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 14(4):1039–1052PubMedCrossRef
69.
Hembruff S, Cheng N (2009) Chemokine signaling in cancer: implications on the tumor microenvironment and therapeutic targeting. Cancer Therapy 7:254–267PubMed
70.
Bacman D, Merkel S, Croner R et al (2007) TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 7:156PubMedCrossRef
71.
Bugge TH, Lund LR, Kombrinck KK et al (1998) Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16(24):3097–3104PubMedCrossRef
72.
Chytil A, Magnuson MA, Wright CVE et al (2002) Conditional inactivation of the TGF-B type II receptor using Cre-Lox. Genesis 32:73–75PubMedCrossRef
73.
Medina D, Kittrell F (2000) Establishment of mouse mammary cell lines. In: Ip MM, Asch BB (eds) Methods in mammary gland biology and breast cancer research. Kluwer Academic/Plenum Publishers, New York, pp 137–147
74.
Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP (2000) A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 2(14):187–197
Metadata
Title
Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression
Authors
Wei Bin Fang
Iman Jokar
Anna Chytil
Harold L. Moses
Ty Abel
Nikki Cheng
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2011
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-011-9373-0

Other articles of this Issue 4/2011

Clinical & Experimental Metastasis 4/2011 Go to the issue

Research Paper

Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice

Research Paper

The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells

Research Paper

Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells

Review

Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management

Research Paper

Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis

Research Paper

c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits